Abstract: The techniques described herein enable a user that sends an email message that includes encrypted content to define a time period during which a recipient of the encrypted content has decrypted access rights. To effectively define the time period, the user can set a time at which the decrypted access rights for the recipient expire. The time occurs after a time at which the email message is sent to the recipient. Upon expiration of the time period, the decrypted access rights to the encrypted content is revoked for the recipient of the email message, thereby providing a proactive element of security for confidential and/or sensitive information. Further, the techniques enable a user to revoke decrypted access rights to the encrypted content for a recipients at any given time after the email message has already been sent, thereby adding a reactive element of security for confidential and/or sensitive information.

Abstract: The techniques described herein enable a user that sends an email message that includes encrypted content to define a time period during which a recipient of the encrypted content has decrypted access rights. To effectively define the time period, the user can set a time at which the decrypted access rights for the recipient expire. The time occurs after a time at which the email message is sent to the recipient. Upon expiration of the time period, the decrypted access rights to the encrypted content is revoked for the recipient of the email message, thereby providing a proactive element of security for confidential and/or sensitive information. Further, the techniques enable a user to revoke decrypted access rights to the encrypted content for a recipients at any given time after the email message has already been sent, thereby adding a reactive element of security for confidential and/or sensitive information.

Abstract: The present invention is directed to pharmaceutical vaginal cream compositions comprising a conjugated estrogen and a stabilizer. The present invention is also directed to a method of treating a menopausal condition in a female in need thereof, said method comprising vaginally administering a pharmaceutical vaginal cream composition comprising a conjugated estrogen twice per week for at least 2 weeks.

Abstract: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of the pharmaceutical compositions.

Abstract: The present invention is directed to flexible, compressed intravaginal rings comprising a substantially homogeneous compressed mixture comprising a polymethacrylate, a plasticizer, and an active agent, and methods of making and using the same, and apparatus for making the same.

Abstract: The present invention is generally directed to pharmaceutical compositions and process for the preparation of same which are suitable for oral administration to a human patient, comprising: a pharmaceutically-acceptable salt of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid; a non-reducing sugar diluent; a binder; a disintegrant; and a lubricant, and various other excipients.

Abstract: The present invention is directed to monophasic pharmaceutical compositions comprising a conjugated estrogen and a hydrophilic or lipophilic excipient. The present invention is also directed to kits and applicators comprising the pharmaceutical compositions. The invention is also directed to methods for treating menopausal conditions in a female comprising administration of the pharmaceutical compositions.

Abstract: The present invention is directed to vaginal tablets comprising misoprostol and a pharmaceutically acceptable pH insensitive, hydrophilic cellulose material, wherein the vaginal tablets do not contain a hydrophobic release controlling agent, and wherein the misoprostol and the pharmaceutically acceptable pH insensitive, hydrophilic cellulose material are in a ratio of about 1:50 to about 1:800, and wherein the vaginal tablets do not substantially change the pH of a vaginal tract.

Abstract: The present invention relates to coated capsules with increased capsule shell pliability and resilience and methods of making the coated capsules. The present invention relates to methods of making coated capsules, the methods comprising applying a coating solution comprising sodium carboxymethylcellulose or sodium alginate to the exterior of a capsule to form a coating and drying the coating to produce a coated capsule.

Abstract: The present invention provides flexible solid dosage forms that include an active agent, gelatin, and a polyol or saccharide. The present invention also provides methods of making flexible solid dosage forms.

Abstract: The present invention relates to an oral pharmaceutical dosage form comprising micronized progesterone, an edible oil, a disintegrant, and a hydrophilic excipient. Particularly, the invention relates to a pharmaceutical dosage form wherein the dosage form is in a powder form and is contained in a pharmaceutically acceptable capsule. The present invention is also directed toward methods of making the dosage form, methods of using the dosage form, and kits comprising the dosage form.

Abstract: The present invention relates to pharmaceutical compositions comprising an estrogen and a progestin in solution, and a teratogen suspended in the estrogen and progestin solution. The present invention also relates to methods of making and using the pharmaceutical compositions described herein.

Abstract: The present invention is directed to pharmaceutical vaginal cream compositions comprising a conjugated estrogen and a stabilizer. The present invention is also directed to a method of treating a menopausal condition in a female in need thereof, said method comprising vaginally administering a pharmaceutical vaginal cream composition comprising a conjugated estrogen twice per week for at least 2 weeks.

Abstract: The present invention is directed to pharmaceutical compositions comprising sumatriptan succinate and sodium caprate for increased absorption of sumatriptan succinate across biological membranes. The invention is also directed to methods of making the pharmaceutical compositions and uses thereof.

Abstract: The present invention relates to novel formulations of methotrexate in liquid form that are suitable for oral use.

Abstract: The present invention is directed to a method of preparing a pharmaceutical dosage form, the method comprising (a) encasing a pharmaceutical dosage form comprising an estrogen in a container essentially impervious to oxygen, and (b) purging the container with an inert gas, and pharmaceutical dosages formed by the method thereof. The present invention is also directed to a pharmaceutical kit comprising (a) a container impervious to oxygen, wherein the container contains an atmosphere of essentially inert gas, and (b) a pharmaceutical dosage form, wherein the pharmaceutical dosage form comprises an estrogen and wherein the pharmaceutical dosage form is encased in the container.